Stem definition | Drug id | CAS RN |
---|---|---|
histamine-H2-receptor antagonists, cimetidine derivatives | 1129 | 76824-35-6 |
Dose | Unit | Route |
---|---|---|
40 | mg | O |
40 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 67 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.98 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 42 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 6.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 15, 1986 | FDA | VALEANT PHARMS NORTH |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 368.70 | 9.42 | 764 | 114797 | 816481 | 52417024 |
Rheumatoid arthritis | 314.76 | 9.42 | 144 | 115417 | 314387 | 52919118 |
Contraindicated product administered | 237.52 | 9.42 | 14 | 115547 | 135615 | 53097890 |
Synovitis | 209.71 | 9.42 | 5 | 115556 | 107888 | 53125617 |
Drug intolerance | 200.86 | 9.42 | 97 | 115464 | 205396 | 53028109 |
Joint swelling | 158.14 | 9.42 | 165 | 115396 | 234473 | 52999032 |
Hand deformity | 147.78 | 9.42 | 9 | 115552 | 84840 | 53148665 |
Treatment failure | 146.04 | 9.42 | 48 | 115513 | 128355 | 53105150 |
Systemic lupus erythematosus | 138.95 | 9.42 | 49 | 115512 | 125365 | 53108140 |
Glossodynia | 134.10 | 9.42 | 27 | 115534 | 100264 | 53133241 |
Therapeutic product effect decreased | 127.84 | 9.42 | 56 | 115505 | 125599 | 53107906 |
Arthropathy | 126.08 | 9.42 | 75 | 115486 | 141378 | 53092127 |
Hepatic function abnormal | 122.06 | 9.42 | 256 | 115305 | 36643 | 53196862 |
Gastrooesophageal reflux disease | 119.95 | 9.42 | 423 | 115138 | 82240 | 53151265 |
Pneumonia aspiration | 114.65 | 9.42 | 239 | 115322 | 34062 | 53199443 |
Chronic kidney disease | 104.92 | 9.42 | 266 | 115295 | 43104 | 53190401 |
Platelet count decreased | 104.05 | 9.42 | 487 | 115074 | 107612 | 53125893 |
White blood cell count decreased | 103.60 | 9.42 | 538 | 115023 | 123937 | 53109568 |
Maternal exposure during pregnancy | 87.32 | 9.42 | 126 | 115435 | 155513 | 53077992 |
Lower respiratory tract infection | 85.72 | 9.42 | 45 | 115516 | 90936 | 53142569 |
Wound | 85.21 | 9.42 | 46 | 115515 | 91511 | 53141994 |
Pericarditis | 84.72 | 9.42 | 18 | 115543 | 64388 | 53169117 |
Drug abuse | 78.98 | 9.42 | 22 | 115539 | 65504 | 53168001 |
Toxicity to various agents | 75.93 | 9.42 | 234 | 115327 | 219364 | 53014141 |
Alopecia | 73.52 | 9.42 | 261 | 115300 | 234322 | 52999183 |
Disseminated intravascular coagulation | 65.42 | 9.42 | 137 | 115424 | 19582 | 53213923 |
Hepatic enzyme increased | 62.43 | 9.42 | 111 | 115450 | 126084 | 53107421 |
Off label use | 61.72 | 9.42 | 690 | 114871 | 471522 | 52761983 |
General physical health deterioration | 60.21 | 9.42 | 144 | 115417 | 146798 | 53086707 |
Helicobacter infection | 60.21 | 9.42 | 7 | 115554 | 39062 | 53194443 |
Aspartate aminotransferase increased | 59.03 | 9.42 | 347 | 115214 | 83682 | 53149823 |
Duodenal ulcer perforation | 57.61 | 9.42 | 5 | 115556 | 35178 | 53198327 |
Neutrophil count decreased | 56.95 | 9.42 | 234 | 115327 | 48864 | 53184641 |
Product use issue | 55.45 | 9.42 | 139 | 115422 | 139445 | 53094060 |
Arthralgia | 54.56 | 9.42 | 650 | 114911 | 439133 | 52794372 |
Cholecystitis chronic | 53.72 | 9.42 | 88 | 115473 | 10430 | 53223075 |
Musculoskeletal stiffness | 52.87 | 9.42 | 118 | 115443 | 123250 | 53110255 |
Flushing | 50.52 | 9.42 | 293 | 115268 | 70307 | 53163198 |
Discomfort | 49.02 | 9.42 | 82 | 115479 | 95390 | 53138115 |
Blood lactate dehydrogenase increased | 48.97 | 9.42 | 130 | 115431 | 21651 | 53211854 |
Liver disorder | 48.65 | 9.42 | 194 | 115367 | 39961 | 53193544 |
Swelling | 48.35 | 9.42 | 231 | 115330 | 190874 | 53042631 |
Folliculitis | 48.08 | 9.42 | 6 | 115555 | 31703 | 53201802 |
Dehydration | 46.71 | 9.42 | 564 | 114997 | 167846 | 53065659 |
Butterfly rash | 45.69 | 9.42 | 29 | 115532 | 1078 | 53232427 |
Drug hypersensitivity | 45.52 | 9.42 | 362 | 115199 | 264880 | 52968625 |
Alanine aminotransferase increased | 45.41 | 9.42 | 357 | 115204 | 94738 | 53138767 |
Angioedema | 45.27 | 9.42 | 196 | 115365 | 41880 | 53191625 |
Therapeutic product effect incomplete | 43.37 | 9.42 | 83 | 115478 | 91701 | 53141804 |
Hepatocellular injury | 42.37 | 9.42 | 7 | 115554 | 29979 | 53203526 |
Interstitial lung disease | 39.82 | 9.42 | 240 | 115321 | 58382 | 53175123 |
Pain | 38.73 | 9.42 | 975 | 114586 | 587423 | 52646082 |
Ill-defined disorder | 37.69 | 9.42 | 31 | 115530 | 49413 | 53184092 |
Anaphylactic reaction | 36.00 | 9.42 | 233 | 115328 | 58093 | 53175412 |
Upper respiratory tract inflammation | 35.17 | 9.42 | 37 | 115524 | 2837 | 53230668 |
Abdominal discomfort | 35.06 | 9.42 | 308 | 115253 | 220754 | 53012751 |
Completed suicide | 34.97 | 9.42 | 167 | 115394 | 138034 | 53095471 |
Enterocolitis | 34.67 | 9.42 | 58 | 115503 | 6994 | 53226511 |
Mobility decreased | 34.29 | 9.42 | 71 | 115490 | 76200 | 53157305 |
Torsade de pointes | 33.80 | 9.42 | 82 | 115479 | 12923 | 53220582 |
Urticaria | 32.96 | 9.42 | 444 | 115117 | 135441 | 53098064 |
Knee arthroplasty | 32.51 | 9.42 | 16 | 115545 | 33553 | 53199952 |
Sopor | 31.94 | 9.42 | 4 | 115557 | 21080 | 53212425 |
Chest discomfort | 30.34 | 9.42 | 340 | 115221 | 99355 | 53134150 |
Cerebral infarction | 30.33 | 9.42 | 119 | 115442 | 24325 | 53209180 |
Urinary tract infection | 30.16 | 9.42 | 706 | 114855 | 239197 | 52994308 |
Diarrhoea | 29.99 | 9.42 | 1648 | 113913 | 623898 | 52609607 |
Gallbladder disorder | 29.88 | 9.42 | 97 | 115464 | 18068 | 53215437 |
Periorbital oedema | 29.24 | 9.42 | 46 | 115515 | 5269 | 53228236 |
Lip swelling | 28.71 | 9.42 | 126 | 115435 | 27075 | 53206430 |
Mental status changes | 28.15 | 9.42 | 164 | 115397 | 39407 | 53194098 |
End stage renal disease | 28.03 | 9.42 | 49 | 115512 | 6122 | 53227383 |
Exposure during pregnancy | 26.52 | 9.42 | 160 | 115401 | 124700 | 53108805 |
Red blood cell sedimentation rate increased | 26.23 | 9.42 | 14 | 115547 | 28043 | 53205462 |
Psoriatic arthropathy | 26.04 | 9.42 | 40 | 115521 | 48150 | 53185355 |
Overdose | 25.63 | 9.42 | 133 | 115428 | 107603 | 53125902 |
Drug resistance | 23.50 | 9.42 | 7 | 115554 | 19955 | 53213550 |
Constipation | 23.43 | 9.42 | 579 | 114982 | 197833 | 53035672 |
Haemorrhage subcutaneous | 23.21 | 9.42 | 31 | 115530 | 3060 | 53230445 |
Impaired healing | 23.17 | 9.42 | 67 | 115494 | 64138 | 53169367 |
Febrile neutropenia | 23.06 | 9.42 | 337 | 115224 | 104599 | 53128906 |
Pneumonia | 22.99 | 9.42 | 1090 | 114471 | 406079 | 52827426 |
Foetal exposure during pregnancy | 22.68 | 9.42 | 25 | 115536 | 34690 | 53198815 |
Loss of personal independence in daily activities | 22.28 | 9.42 | 77 | 115484 | 69738 | 53163767 |
Decreased appetite | 22.11 | 9.42 | 616 | 114945 | 214358 | 53019147 |
Blood alkaline phosphatase increased | 21.25 | 9.42 | 158 | 115403 | 41204 | 53192301 |
Renal injury | 21.14 | 9.42 | 58 | 115503 | 9846 | 53223659 |
Basophil count decreased | 20.64 | 9.42 | 8 | 115553 | 98 | 53233407 |
Acute respiratory failure | 20.60 | 9.42 | 127 | 115434 | 31131 | 53202374 |
Hip arthroplasty | 20.58 | 9.42 | 18 | 115543 | 27844 | 53205661 |
Lymphocyte stimulation test positive | 20.14 | 9.42 | 14 | 115547 | 607 | 53232898 |
Nausea | 20.10 | 9.42 | 1899 | 113662 | 754192 | 52479313 |
Dyspepsia | 19.82 | 9.42 | 256 | 115305 | 77344 | 53156161 |
Hypoxia | 19.80 | 9.42 | 196 | 115365 | 55484 | 53178021 |
Pyrexia | 19.80 | 9.42 | 1065 | 114496 | 402128 | 52831377 |
Biliary dyskinesia | 19.71 | 9.42 | 27 | 115534 | 2730 | 53230775 |
Infective pulmonary exacerbation of cystic fibrosis | 19.65 | 9.42 | 61 | 115500 | 11095 | 53222410 |
Chest pain | 19.56 | 9.42 | 545 | 115016 | 189640 | 53043865 |
Ventricular tachycardia | 19.30 | 9.42 | 83 | 115478 | 17679 | 53215826 |
Coma | 18.92 | 9.42 | 211 | 115350 | 61572 | 53171933 |
Dizziness | 18.61 | 9.42 | 985 | 114576 | 371274 | 52862231 |
Acquired haemophilia | 18.56 | 9.42 | 16 | 115545 | 956 | 53232549 |
Hospice care | 18.51 | 9.42 | 41 | 115520 | 6089 | 53227416 |
Palmar erythema | 18.28 | 9.42 | 20 | 115541 | 1604 | 53231901 |
Blood potassium decreased | 18.27 | 9.42 | 150 | 115411 | 40310 | 53193195 |
Fibromyalgia | 18.19 | 9.42 | 43 | 115518 | 44032 | 53189473 |
Neuropathy peripheral | 18.03 | 9.42 | 319 | 115242 | 102868 | 53130637 |
Drug eruption | 17.85 | 9.42 | 104 | 115457 | 24990 | 53208515 |
Cytokine release syndrome | 17.75 | 9.42 | 48 | 115513 | 8081 | 53225424 |
Serotonin syndrome | 17.27 | 9.42 | 19 | 115542 | 26387 | 53207118 |
Rebound acid hypersecretion | 17.01 | 9.42 | 10 | 115551 | 323 | 53233182 |
Respiratory alkalosis | 16.97 | 9.42 | 25 | 115536 | 2703 | 53230802 |
Premature baby | 16.93 | 9.42 | 11 | 115550 | 19790 | 53213715 |
Throat irritation | 16.83 | 9.42 | 122 | 115439 | 31559 | 53201946 |
Cholecystitis acute | 16.81 | 9.42 | 46 | 115515 | 7797 | 53225708 |
Rheumatoid nodule | 16.26 | 9.42 | 3 | 115558 | 11861 | 53221644 |
Hepatotoxicity | 16.18 | 9.42 | 22 | 115539 | 27858 | 53205647 |
Full blood count decreased | 16.07 | 9.42 | 98 | 115463 | 23931 | 53209574 |
Arthritis | 15.95 | 9.42 | 117 | 115444 | 87181 | 53146324 |
Cystitis noninfective | 15.92 | 9.42 | 14 | 115547 | 859 | 53232646 |
Erythema multiforme | 15.90 | 9.42 | 54 | 115507 | 10295 | 53223210 |
Gastrointestinal disorder | 15.79 | 9.42 | 122 | 115439 | 89882 | 53143623 |
Gallbladder injury | 15.67 | 9.42 | 17 | 115544 | 1350 | 53232155 |
Gastritis | 15.65 | 9.42 | 133 | 115428 | 36101 | 53197404 |
Swelling face | 15.62 | 9.42 | 191 | 115370 | 56977 | 53176528 |
Abdominal distension | 15.51 | 9.42 | 251 | 115310 | 79539 | 53153966 |
Lupus hepatitis | 15.49 | 9.42 | 5 | 115556 | 34 | 53233471 |
Cholinergic syndrome | 15.44 | 9.42 | 10 | 115551 | 385 | 53233120 |
Injection site reaction | 15.29 | 9.42 | 58 | 115503 | 51108 | 53182397 |
Protein total decreased | 15.19 | 9.42 | 37 | 115524 | 5846 | 53227659 |
Sepsis | 15.15 | 9.42 | 420 | 115141 | 146009 | 53087496 |
Muscle spasticity | 15.13 | 9.42 | 10 | 115551 | 17828 | 53215677 |
Throat tightness | 15.11 | 9.42 | 91 | 115470 | 22125 | 53211380 |
Drug interaction | 15.01 | 9.42 | 361 | 115200 | 218968 | 53014537 |
Injection site pain | 15.00 | 9.42 | 165 | 115396 | 113226 | 53120279 |
Device expulsion | 14.93 | 9.42 | 26 | 115535 | 29787 | 53203718 |
Anaphylactoid reaction | 14.88 | 9.42 | 28 | 115533 | 3703 | 53229802 |
Hereditary angioedema | 14.75 | 9.42 | 38 | 115523 | 6215 | 53227290 |
Hypokalaemia | 14.65 | 9.42 | 292 | 115269 | 96225 | 53137280 |
Blister | 14.65 | 9.42 | 105 | 115456 | 78648 | 53154857 |
Haematocrit decreased | 14.56 | 9.42 | 134 | 115427 | 37197 | 53196308 |
Cholestasis | 14.39 | 9.42 | 25 | 115536 | 28670 | 53204835 |
Somnolence | 14.37 | 9.42 | 470 | 115091 | 167264 | 53066241 |
Blood pressure fluctuation | 14.32 | 9.42 | 35 | 115526 | 35435 | 53198070 |
White blood cell count increased | 14.19 | 9.42 | 158 | 115403 | 46087 | 53187418 |
Amino acid level decreased | 14.17 | 9.42 | 5 | 115556 | 46 | 53233459 |
Red blood cell count decreased | 14.06 | 9.42 | 129 | 115432 | 35774 | 53197731 |
Cholelithiasis | 13.99 | 9.42 | 143 | 115418 | 40821 | 53192684 |
Burkholderia test positive | 13.92 | 9.42 | 6 | 115555 | 98 | 53233407 |
Weight increased | 13.91 | 9.42 | 337 | 115224 | 204230 | 53029275 |
Injection site bruising | 13.79 | 9.42 | 39 | 115522 | 37607 | 53195898 |
Congenital neuropathy | 13.77 | 9.42 | 4 | 115557 | 18 | 53233487 |
Disease progression | 13.73 | 9.42 | 303 | 115258 | 101617 | 53131888 |
Intentional self-injury | 13.64 | 9.42 | 21 | 115540 | 25263 | 53208242 |
Victim of chemical submission | 13.54 | 9.42 | 8 | 115553 | 261 | 53233244 |
Hyperuricaemia | 13.51 | 9.42 | 33 | 115528 | 5223 | 53228282 |
Small intestinal obstruction | 13.47 | 9.42 | 73 | 115488 | 17074 | 53216431 |
Tubulointerstitial nephritis | 13.47 | 9.42 | 71 | 115490 | 16433 | 53217072 |
Blood magnesium decreased | 13.45 | 9.42 | 56 | 115505 | 11758 | 53221747 |
Lactic acidosis | 13.35 | 9.42 | 39 | 115522 | 37214 | 53196291 |
Irritable bowel syndrome | 13.33 | 9.42 | 49 | 115512 | 43583 | 53189922 |
Granulocytopenia | 13.33 | 9.42 | 34 | 115527 | 5526 | 53227979 |
Dyspnoea | 13.31 | 9.42 | 1457 | 114104 | 584775 | 52648730 |
Breast adenoma | 13.22 | 9.42 | 5 | 115556 | 57 | 53233448 |
Medication error | 13.08 | 9.42 | 38 | 115523 | 36327 | 53197178 |
Allergy test positive | 13.03 | 9.42 | 9 | 115552 | 386 | 53233119 |
Pyuria | 12.99 | 9.42 | 18 | 115543 | 1840 | 53231665 |
Cytomegalovirus enterocolitis | 12.92 | 9.42 | 11 | 115550 | 646 | 53232859 |
Therapeutic response decreased | 12.90 | 9.42 | 56 | 115505 | 47513 | 53185992 |
Brain natriuretic peptide increased | 12.74 | 9.42 | 31 | 115530 | 4894 | 53228611 |
Putamen haemorrhage | 12.72 | 9.42 | 7 | 115554 | 199 | 53233306 |
Ileus | 12.67 | 9.42 | 65 | 115496 | 14890 | 53218615 |
Hypoparathyroidism | 12.41 | 9.42 | 11 | 115550 | 682 | 53232823 |
Laboratory test abnormal | 12.40 | 9.42 | 93 | 115468 | 24316 | 53209189 |
Asteatosis | 12.36 | 9.42 | 5 | 115556 | 69 | 53233436 |
Swollen tongue | 12.34 | 9.42 | 112 | 115449 | 30968 | 53202537 |
Blood bilirubin increased | 12.33 | 9.42 | 125 | 115436 | 35605 | 53197900 |
Extrapyramidal disorder | 11.87 | 9.42 | 6 | 115555 | 12396 | 53221109 |
Gastrointestinal haemorrhage | 11.85 | 9.42 | 242 | 115319 | 80088 | 53153417 |
Xanthogranuloma | 11.81 | 9.42 | 3 | 115558 | 7 | 53233498 |
Impaired work ability | 11.81 | 9.42 | 8 | 115553 | 14082 | 53219423 |
Stress cardiomyopathy | 11.71 | 9.42 | 43 | 115518 | 8519 | 53224986 |
Blood urea increased | 11.71 | 9.42 | 97 | 115464 | 26134 | 53207371 |
Osteoarthritis | 11.69 | 9.42 | 97 | 115464 | 70389 | 53163116 |
Neurological examination abnormal | 11.64 | 9.42 | 7 | 115554 | 236 | 53233269 |
Infection | 11.62 | 9.42 | 284 | 115277 | 171921 | 53061584 |
Atrioventricular block complete | 11.60 | 9.42 | 41 | 115520 | 7974 | 53225531 |
Condition aggravated | 11.53 | 9.42 | 526 | 115035 | 296608 | 52936897 |
Back pain | 11.51 | 9.42 | 619 | 114942 | 233628 | 52999877 |
Therapy non-responder | 11.47 | 9.42 | 61 | 115500 | 49059 | 53184446 |
Feeling hot | 11.43 | 9.42 | 139 | 115422 | 41405 | 53192100 |
Plasma cell myeloma | 11.41 | 9.42 | 156 | 115405 | 47718 | 53185787 |
Blood creatine phosphokinase MB increased | 11.39 | 9.42 | 14 | 115547 | 1272 | 53232233 |
Liver injury | 11.32 | 9.42 | 19 | 115542 | 22084 | 53211421 |
Haemoglobin decreased | 11.31 | 9.42 | 383 | 115178 | 136924 | 53096581 |
Hypoalbuminaemia | 11.04 | 9.42 | 50 | 115511 | 10886 | 53222619 |
Intraductal papillary breast neoplasm | 11.03 | 9.42 | 3 | 115558 | 10 | 53233495 |
Contusion | 11.02 | 9.42 | 171 | 115390 | 110561 | 53122944 |
Musculoskeletal pain | 10.94 | 9.42 | 107 | 115454 | 75093 | 53158412 |
Chills | 10.92 | 9.42 | 301 | 115260 | 104547 | 53128958 |
Anaemia | 10.91 | 9.42 | 717 | 114844 | 276001 | 52957504 |
Coronary artery dissection | 10.90 | 9.42 | 11 | 115550 | 803 | 53232702 |
Hyperlipidaemia | 10.86 | 9.42 | 76 | 115485 | 19439 | 53214066 |
Ovarian cancer recurrent | 10.85 | 9.42 | 13 | 115548 | 1150 | 53232355 |
Pulmonary hypertension | 10.83 | 9.42 | 126 | 115435 | 37144 | 53196361 |
Restless arm syndrome | 10.79 | 9.42 | 4 | 115557 | 43 | 53233462 |
Pityriasis lichenoides et varioliformis acuta | 10.55 | 9.42 | 4 | 115557 | 46 | 53233459 |
Pupils unequal | 10.46 | 9.42 | 14 | 115547 | 1385 | 53232120 |
Allergic transfusion reaction | 10.39 | 9.42 | 4 | 115557 | 48 | 53233457 |
Deep vein thrombosis | 10.39 | 9.42 | 244 | 115317 | 82669 | 53150836 |
Dermatitis acneiform | 10.37 | 9.42 | 27 | 115534 | 4443 | 53229062 |
Vascular resistance systemic decreased | 10.33 | 9.42 | 5 | 115556 | 108 | 53233397 |
Reticulocyte percentage increased | 10.24 | 9.42 | 3 | 115558 | 14 | 53233491 |
Myocarditis infectious | 10.24 | 9.42 | 3 | 115558 | 14 | 53233491 |
Inflammation | 10.23 | 9.42 | 77 | 115484 | 57059 | 53176446 |
Blood albumin decreased | 10.17 | 9.42 | 60 | 115501 | 14482 | 53219023 |
Tinea pedis | 10.10 | 9.42 | 14 | 115547 | 1431 | 53232074 |
Lymphocyte count decreased | 10.09 | 9.42 | 99 | 115462 | 27953 | 53205552 |
Ovarian cancer | 10.09 | 9.42 | 33 | 115528 | 6169 | 53227336 |
Therapeutic hypothermia | 10.07 | 9.42 | 3 | 115558 | 15 | 53233490 |
Mean arterial pressure increased | 10.07 | 9.42 | 3 | 115558 | 15 | 53233490 |
Pyelonephritis acute | 10.03 | 9.42 | 27 | 115534 | 4532 | 53228973 |
Seasonal allergy | 10.01 | 9.42 | 62 | 115499 | 15223 | 53218282 |
Haemolytic anaemia | 10.00 | 9.42 | 47 | 115514 | 10392 | 53223113 |
COVID-19 | 9.97 | 9.42 | 123 | 115438 | 36765 | 53196740 |
Hypoaesthesia | 9.97 | 9.42 | 367 | 115194 | 132628 | 53100877 |
Neuroleptic malignant syndrome | 9.86 | 9.42 | 7 | 115554 | 12026 | 53221479 |
Hypergeusia | 9.76 | 9.42 | 3 | 115558 | 17 | 53233488 |
Histamine level increased | 9.76 | 9.42 | 3 | 115558 | 17 | 53233488 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 148.93 | 9.96 | 478 | 80717 | 382999 | 32049332 |
Hepatic function abnormal | 148.81 | 9.96 | 339 | 80856 | 44501 | 32387830 |
Drug abuse | 119.45 | 9.96 | 27 | 81168 | 80216 | 32352115 |
Platelet count decreased | 100.58 | 9.96 | 557 | 80638 | 114034 | 32318297 |
Alanine aminotransferase increased | 97.96 | 9.96 | 422 | 80773 | 78057 | 32354274 |
Liver disorder | 92.70 | 9.96 | 228 | 80967 | 31426 | 32400905 |
Aspartate aminotransferase increased | 92.15 | 9.96 | 369 | 80826 | 66060 | 32366271 |
Toxicity to various agents | 82.82 | 9.96 | 203 | 80992 | 177838 | 32254493 |
Disseminated intravascular coagulation | 73.30 | 9.96 | 172 | 81023 | 23004 | 32409327 |
White blood cell count decreased | 73.21 | 9.96 | 433 | 80762 | 90765 | 32341566 |
Off label use | 71.58 | 9.96 | 460 | 80735 | 305860 | 32126471 |
Completed suicide | 70.69 | 9.96 | 76 | 81119 | 92441 | 32339890 |
General physical health deterioration | 66.60 | 9.96 | 116 | 81079 | 115143 | 32317188 |
Drug interaction | 55.95 | 9.96 | 318 | 80877 | 217867 | 32214464 |
Neutrophil count decreased | 55.37 | 9.96 | 249 | 80946 | 46890 | 32385441 |
Chronic kidney disease | 46.82 | 9.96 | 211 | 80984 | 39764 | 32392567 |
Blood lactate dehydrogenase increased | 45.76 | 9.96 | 139 | 81056 | 21666 | 32410665 |
Rheumatoid arthritis | 43.29 | 9.96 | 29 | 81166 | 44515 | 32387816 |
Drug resistance | 40.17 | 9.96 | 5 | 81190 | 22960 | 32409371 |
Interstitial lung disease | 38.41 | 9.96 | 286 | 80909 | 64715 | 32367616 |
Treatment failure | 37.39 | 9.96 | 26 | 81169 | 39137 | 32393194 |
Upper respiratory tract inflammation | 34.92 | 9.96 | 33 | 81162 | 1924 | 32430407 |
Blood alkaline phosphatase increased | 33.52 | 9.96 | 164 | 81031 | 31968 | 32400363 |
Cerebral infarction | 33.26 | 9.96 | 147 | 81048 | 27467 | 32404864 |
Foetal exposure during pregnancy | 31.44 | 9.96 | 34 | 81161 | 41267 | 32391064 |
Lymphocyte stimulation test positive | 30.86 | 9.96 | 22 | 81173 | 859 | 32431472 |
Product use in unapproved indication | 30.71 | 9.96 | 113 | 81082 | 87091 | 32345240 |
Overdose | 29.90 | 9.96 | 114 | 81081 | 86963 | 32345368 |
Infusion related reaction | 29.45 | 9.96 | 205 | 80990 | 45394 | 32386937 |
Pyrexia | 27.39 | 9.96 | 1016 | 80179 | 318952 | 32113379 |
Pneumonitis | 27.39 | 9.96 | 148 | 81047 | 29986 | 32402345 |
Contraindicated product administered | 25.37 | 9.96 | 8 | 81187 | 19068 | 32413263 |
Psoriasis | 25.20 | 9.96 | 48 | 81147 | 46075 | 32386256 |
Decreased appetite | 25.01 | 9.96 | 551 | 80644 | 160262 | 32272069 |
Therapeutic product effect incomplete | 24.40 | 9.96 | 41 | 81154 | 41300 | 32391031 |
End stage renal disease | 23.63 | 9.96 | 58 | 81137 | 7979 | 32424352 |
Drug intolerance | 23.51 | 9.96 | 57 | 81138 | 50178 | 32382153 |
Haematocrit decreased | 22.64 | 9.96 | 146 | 81049 | 31516 | 32400815 |
Pneumonia | 22.28 | 9.96 | 1092 | 80103 | 354160 | 32078171 |
Blood creatine phosphokinase MB increased | 22.13 | 9.96 | 26 | 81169 | 1951 | 32430380 |
Blood bilirubin increased | 21.97 | 9.96 | 169 | 81026 | 38615 | 32393716 |
Acute respiratory failure | 21.49 | 9.96 | 134 | 81061 | 28594 | 32403737 |
Pneumonia bacterial | 21.26 | 9.96 | 67 | 81128 | 10649 | 32421682 |
Rash | 20.95 | 9.96 | 677 | 80518 | 208656 | 32223675 |
Blood urea increased | 20.20 | 9.96 | 144 | 81051 | 32129 | 32400202 |
Blood albumin decreased | 19.60 | 9.96 | 74 | 81121 | 12879 | 32419452 |
Enterocolitis | 19.52 | 9.96 | 51 | 81144 | 7289 | 32425042 |
Erythema multiforme | 19.50 | 9.96 | 58 | 81137 | 8934 | 32423397 |
Hypoxia | 19.22 | 9.96 | 207 | 80988 | 51925 | 32380406 |
Lactic acidosis | 19.11 | 9.96 | 34 | 81161 | 33502 | 32398829 |
Urticaria | 18.96 | 9.96 | 230 | 80965 | 59384 | 32372947 |
Intentional product misuse | 18.42 | 9.96 | 39 | 81156 | 36012 | 32396319 |
Cytokine release syndrome | 17.80 | 9.96 | 74 | 81121 | 13461 | 32418870 |
Pneumonia aspiration | 17.36 | 9.96 | 168 | 81027 | 40988 | 32391343 |
Constipation | 17.16 | 9.96 | 425 | 80770 | 125948 | 32306383 |
Human ehrlichiosis | 16.60 | 9.96 | 9 | 81186 | 214 | 32432117 |
Cholangitis acute | 16.47 | 9.96 | 15 | 81180 | 834 | 32431497 |
Mast cell activation syndrome | 16.33 | 9.96 | 8 | 81187 | 153 | 32432178 |
Wound secretion | 16.22 | 9.96 | 26 | 81169 | 2621 | 32429710 |
Intentional product use issue | 15.99 | 9.96 | 53 | 81142 | 42158 | 32390173 |
Hepatocellular injury | 15.99 | 9.96 | 24 | 81171 | 25294 | 32407037 |
Ventricular tachycardia | 15.97 | 9.96 | 114 | 81081 | 25442 | 32406889 |
Blood pressure ambulatory increased | 15.91 | 9.96 | 6 | 81189 | 58 | 32432273 |
PO2 increased | 15.85 | 9.96 | 13 | 81182 | 627 | 32431704 |
Rash maculo-papular | 15.44 | 9.96 | 29 | 81166 | 27993 | 32404338 |
Psychotic disorder | 15.35 | 9.96 | 21 | 81174 | 22999 | 32409332 |
Febrile neutropenia | 15.32 | 9.96 | 399 | 80796 | 119167 | 32313164 |
Intentional overdose | 15.23 | 9.96 | 53 | 81142 | 41548 | 32390783 |
Anaphylactic reaction | 15.19 | 9.96 | 128 | 81067 | 30044 | 32402287 |
Joint swelling | 15.12 | 9.96 | 72 | 81123 | 51663 | 32380668 |
Gastrointestinal mucosal necrosis | 15.11 | 9.96 | 8 | 81187 | 181 | 32432150 |
Glossectomy | 14.99 | 9.96 | 3 | 81192 | 0 | 32432331 |
Catheter site haemorrhage | 14.84 | 9.96 | 23 | 81172 | 2252 | 32430079 |
Infective pulmonary exacerbation of cystic fibrosis | 14.84 | 9.96 | 52 | 81143 | 8727 | 32423604 |
CADASIL | 14.40 | 9.96 | 6 | 81189 | 77 | 32432254 |
Ultrasound skull abnormal | 14.40 | 9.96 | 6 | 81189 | 77 | 32432254 |
Torsade de pointes | 14.38 | 9.96 | 46 | 81149 | 7369 | 32424962 |
Cardiac autonomic neuropathy | 14.20 | 9.96 | 6 | 81189 | 80 | 32432251 |
Magnetic resonance imaging spinal abnormal | 14.13 | 9.96 | 6 | 81189 | 81 | 32432250 |
Lower respiratory tract infection | 13.83 | 9.96 | 33 | 81162 | 29210 | 32403121 |
Visual evoked potentials abnormal | 13.81 | 9.96 | 6 | 81189 | 86 | 32432245 |
Polyneuropathy | 13.67 | 9.96 | 8 | 81187 | 13207 | 32419124 |
Aplastic anaemia | 13.63 | 9.96 | 45 | 81150 | 7328 | 32425003 |
Sepsis | 13.44 | 9.96 | 504 | 80691 | 158330 | 32274001 |
Convulsive threshold lowered | 13.44 | 9.96 | 11 | 81184 | 529 | 32431802 |
Gastrooesophageal reflux disease | 13.30 | 9.96 | 139 | 81056 | 34599 | 32397732 |
Blood pressure decreased | 13.29 | 9.96 | 190 | 81005 | 50890 | 32381441 |
Drug dependence | 13.21 | 9.96 | 24 | 81171 | 23460 | 32408871 |
Convulsions local | 13.21 | 9.96 | 4 | 81191 | 18 | 32432313 |
Hypertensive crisis | 13.04 | 9.96 | 3 | 81192 | 8814 | 32423517 |
Protein total decreased | 12.99 | 9.96 | 35 | 81160 | 5095 | 32427236 |
Hiccups | 12.93 | 9.96 | 54 | 81141 | 9841 | 32422490 |
Pneumonia staphylococcal | 12.85 | 9.96 | 26 | 81169 | 3142 | 32429189 |
Burkholderia test positive | 12.81 | 9.96 | 10 | 81185 | 449 | 32431882 |
Anal erosion | 12.55 | 9.96 | 4 | 81191 | 22 | 32432309 |
Central nervous system inflammation | 12.43 | 9.96 | 6 | 81189 | 111 | 32432220 |
Respiratory failure | 12.40 | 9.96 | 353 | 80842 | 106829 | 32325502 |
Supine hypertension | 12.39 | 9.96 | 9 | 81186 | 362 | 32431969 |
Renal impairment | 12.39 | 9.96 | 309 | 80886 | 91663 | 32340668 |
Amino acid level decreased | 12.38 | 9.96 | 5 | 81190 | 59 | 32432272 |
Cerebral microangiopathy | 11.98 | 9.96 | 7 | 81188 | 193 | 32432138 |
Eczema asteatotic | 11.98 | 9.96 | 7 | 81188 | 193 | 32432138 |
Ventricular flutter | 11.87 | 9.96 | 5 | 81190 | 66 | 32432265 |
Double stranded DNA antibody positive | 11.78 | 9.96 | 6 | 81189 | 125 | 32432206 |
Arthropathy | 11.76 | 9.96 | 24 | 81171 | 22465 | 32409866 |
Sputum retention | 11.76 | 9.96 | 10 | 81185 | 507 | 32431824 |
Cardiogenic shock | 11.73 | 9.96 | 21 | 81174 | 20641 | 32411690 |
Nipple swelling | 11.70 | 9.96 | 3 | 81192 | 6 | 32432325 |
Post procedural haematoma | 11.58 | 9.96 | 17 | 81178 | 1587 | 32430744 |
Amino acid level increased | 11.55 | 9.96 | 9 | 81186 | 403 | 32431928 |
Conduction disorder | 11.45 | 9.96 | 19 | 81176 | 1971 | 32430360 |
Jaundice hepatocellular | 11.42 | 9.96 | 5 | 81190 | 73 | 32432258 |
Aggression | 11.40 | 9.96 | 55 | 81140 | 39334 | 32392997 |
Acute kidney injury | 11.40 | 9.96 | 608 | 80587 | 292860 | 32139471 |
Saccadic eye movement | 11.25 | 9.96 | 6 | 81189 | 138 | 32432193 |
White blood cell count increased | 11.17 | 9.96 | 155 | 81040 | 41247 | 32391084 |
Ejaculation delayed | 11.11 | 9.96 | 7 | 81188 | 222 | 32432109 |
Stomatitis | 11.01 | 9.96 | 151 | 81044 | 40078 | 32392253 |
Progressive multifocal leukoencephalopathy | 11.00 | 9.96 | 5 | 81190 | 9526 | 32422805 |
Death | 10.96 | 9.96 | 815 | 80380 | 381702 | 32050629 |
Product use issue | 10.90 | 9.96 | 82 | 81113 | 52695 | 32379636 |
Cholestasis | 10.90 | 9.96 | 33 | 81162 | 27000 | 32405331 |
Granulocyte count decreased | 10.88 | 9.96 | 11 | 81184 | 697 | 32431634 |
Viral rash | 10.84 | 9.96 | 5 | 81190 | 83 | 32432248 |
Laboratory test abnormal | 10.71 | 9.96 | 83 | 81112 | 19004 | 32413327 |
Musculoskeletal stiffness | 10.70 | 9.96 | 56 | 81139 | 39208 | 32393123 |
Hypoalbuminaemia | 10.69 | 9.96 | 58 | 81137 | 11764 | 32420567 |
Haemorrhagic diathesis | 10.60 | 9.96 | 23 | 81172 | 2919 | 32429412 |
Inappropriate schedule of product administration | 10.54 | 9.96 | 69 | 81126 | 45756 | 32386575 |
Granulocytopenia | 10.51 | 9.96 | 38 | 81157 | 6477 | 32425854 |
Blood pH decreased | 10.50 | 9.96 | 20 | 81175 | 2313 | 32430018 |
Sputum culture positive | 10.44 | 9.96 | 18 | 81177 | 1926 | 32430405 |
Stevens-Johnson syndrome | 10.30 | 9.96 | 81 | 81114 | 18628 | 32413703 |
Psoriatic arthropathy | 10.27 | 9.96 | 18 | 81177 | 17842 | 32414489 |
Gastrointestinal tract mucosal pigmentation | 10.27 | 9.96 | 8 | 81187 | 358 | 32431973 |
Depressed level of consciousness | 10.25 | 9.96 | 151 | 81044 | 40696 | 32391635 |
Hepatitis fulminant | 10.23 | 9.96 | 28 | 81167 | 4115 | 32428216 |
Oral pruritus | 10.15 | 9.96 | 7 | 81188 | 259 | 32432072 |
Pancreatic enlargement | 10.05 | 9.96 | 5 | 81190 | 99 | 32432232 |
Urine osmolarity decreased | 9.99 | 9.96 | 4 | 81191 | 46 | 32432285 |
Accidental exposure to product | 9.96 | 9.96 | 8 | 81187 | 11194 | 32421137 |
Aortic rupture | 9.96 | 9.96 | 5 | 81190 | 101 | 32432230 |
Source | Code | Description |
---|---|---|
ATC | A02BA03 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
ATC | A02BA53 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
FDA MoA | N0000000151 | Histamine H2 Receptor Antagonists |
CHEBI has role | CHEBI:37961 | H2-receptor blockers |
CHEBI has role | CHEBI:49201 | anti-ulcer agents |
CHEBI has role | CHEBI:50183 | cytochrome P450 inhibitor |
MeSH PA | D000897 | Anti-Ulcer Agents |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018494 | Histamine Agents |
MeSH PA | D006633 | Histamine Antagonists |
MeSH PA | D006635 | Histamine H2 Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
FDA EPC | N0000175784 | Histamine-2 Receptor Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Heartburn | indication | 16331000 | |
Erosive esophagitis | indication | 40719004 | |
Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
Zollinger-Ellison syndrome | indication | 53132006 | DOID:0050782 |
Peptic reflux disease | indication | 57643001 | |
Indigestion | indication | 162031009 | |
Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
Gastric ulcer | indication | 397825006 | DOID:10808 |
Dyspepsia Prevention | indication | ||
Maintenance of Healing Duodenal Ulcer | indication | ||
Heartburn Prevention | indication | ||
Upper gastrointestinal hemorrhage | off-label use | 37372002 | |
Prevention of Stress Ulcer | off-label use | ||
Constipation | contraindication | 14760008 | DOID:2089 |
Sarcoidosis | contraindication | 31541009 | DOID:11335 |
Dehydration | contraindication | 34095006 | |
Diarrhea | contraindication | 62315008 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 | |
Impaired renal function disorder | contraindication | 197663003 | |
Osteolysis | contraindication | 203522001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Malignant tumor of stomach | contraindication | 363349007 | DOID:10534 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.84 | acidic |
pKa2 | 12.0 | acidic |
pKa3 | 6.97 | Basic |
pKa4 | 6.37 | Basic |
pKa5 | 2.56 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
26.6MG;800MG | DUEXIS | HORIZON | N022519 | April 23, 2011 | RX | TABLET | ORAL | 8067451 | July 18, 2026 | RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS |
26.6MG;800MG | DUEXIS | HORIZON | N022519 | April 23, 2011 | RX | TABLET | ORAL | 8501228 | July 18, 2026 | RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Histamine H2 receptor | GPCR | ANTAGONIST | Kd | 7.93 | WOMBAT-PK | CHEMBL | |||
Carbonic anhydrase 2 | Enzyme | Ki | 7.24 | CHEMBL | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 6.04 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 6.03 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 6.90 | CHEMBL | |||||
Carbonic anhydrase 12 | Enzyme | Ki | 7.34 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 5.84 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 5.27 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 8.52 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 7.01 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 6.17 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 6.77 | CHEMBL | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 4.44 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 6.12 | CHEMBL | |||||
Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 4.44 | CHEMBL | |||||
Heat shock protein HSP 90-alpha | Cytosolic other | IC50 | 5.30 | WOMBAT-PK | |||||
Solute carrier family 22 member 3 | Transporter | IC50 | 4.97 | CHEMBL | |||||
Histamine H2 receptor | GPCR | Kd | 7 | CHEMBL |
ID | Source |
---|---|
4017970 | VUID |
N0000146320 | NUI |
D00318 | KEGG_DRUG |
4017970 | VANDF |
C0015620 | UMLSCUI |
CHEBI:4975 | CHEBI |
FO9 | PDB_CHEM_ID |
CHEMBL902 | ChEMBL_ID |
DB00927 | DRUGBANK_ID |
D015738 | MESH_DESCRIPTOR_UI |
5353622 | PUBCHEM_CID |
7074 | IUPHAR_LIGAND_ID |
5217 | INN_ID |
5QZO15J2Z8 | UNII |
4278 | RXNORM |
41331 | MMSL |
4713 | MMSL |
d00141 | MMSL |
003417 | NDDF |
387211002 | SNOMEDCT_US |
39128000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Ibuprofen and famotidine | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-8107 | TABLET, FILM COATED | 26.60 mg | ORAL | ANDA | 28 sections |
Good Sense Dual Action Complete | HUMAN OTC DRUG LABEL | 3 | 0113-0032 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
good sense acid reducer | HUMAN OTC DRUG LABEL | 1 | 0113-0141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Good Sense Acid Reducer | HUMAN OTC DRUG LABEL | 1 | 0113-0194 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
basic care acid reducer | HUMAN OTC DRUG LABEL | 1 | 0113-7141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Basic Care famotidine | HUMAN OTC DRUG LABEL | 1 | 0113-7194 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 14 sections |
basic care dual action complete | HUMAN OTC DRUG LABEL | 3 | 0113-7321 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0172-5728 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 25 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0172-5729 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 25 sections |
Pepcid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-4420 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 25 sections |
Pepcid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-4440 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 25 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-5197 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 22 sections |
Acid ControllerOriginal Strength | HUMAN OTC DRUG LABEL | 1 | 0363-0141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Acid Reducer Complete | HUMAN OTC DRUG LABEL | 3 | 0363-0511 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
Acid Controller | HUMAN OTC DRUG LABEL | 1 | 0363-0701 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
Acid Reducer Complete | HUMAN OTC DRUG LABEL | 3 | 0363-0713 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
Famotidine | Human OTC Drug Label | 1 | 0363-1899 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 16 sections |
Famotidine | Human OTC Drug Label | 1 | 0363-4400 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 16 sections |
Famotidine | Human OTC Drug Label | 1 | 0363-5300 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 16 sections |
Rugby Famotidine | HUMAN OTC DRUG LABEL | 1 | 0536-1298 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-4582 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 20 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8301 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 20 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6021 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6022 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6023 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
heartburn relieforiginal strength | HUMAN OTC DRUG LABEL | 1 | 0904-5529 | TABLET | 10 mg | ORAL | ANDA | 15 sections |
Major Heartburn ReliefMaximum Strength | HUMAN OTC DRUG LABEL | 1 | 0904-5780 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7193 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 24 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-481 | TABLET | 20 mg | ORAL | ANDA | 21 sections |
up and up famotidine complete | HUMAN OTC DRUG LABEL | 3 | 11673-007 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |